BridgeBio

10/29/2026

“It's very risky to invest in one drug because of that binary outcome. But what if we invested in, I don't know, 150 of them all at the same time?” – Andrew Lo, Ph.D., Massachusetts Institute of Technology

Noa is one of more than 30 million Americans living with a rare disease.

Fewer than 5% of rare diseases have an FDA-approved treatment. For most families, a diagnosis still arrives with no answer attached — and they wait.

Noa's Story is about what changed, and about the parents, researchers, and advocates who refused to accept that answer.

Our thanks to the Greenwood family for sharing Noa with us, and to the UMass Chan Medical School for the years of work behind this moment.

Watch the full video on our Insights page: https://bit.ly/4z9U5fL

10/28/2026

For people living with chronic considering a can also mean thinking about visits, travel, and everyday responsibilities. Here, we share where RECLAIM-HP Study activities may take place and the support available for eligible costs related to study visits.

10/27/2026

We’re bringing no-charge genetic testing to Denver. Stop by our mobile genetic testing van.

We're offering no-charge genetic testing for ADH1, a common genetic form of hypoparathyroidism. In a sponsored genetic testing cohort, ADH1 was identified in approximately 20% of participants, and it's often misdiagnosed for years without knowing the genetic cause of their symptoms.

Testing may be worth considering if you or a family member has:
• Low blood calcium with high calcium in the urine, and low PTH
• Severe muscle cramps, tetany, or tingling in the hands or feet
• Seizures with no other clear explanation
• Recurring kidney stones, nephrocalcinosis, or unexplained changes in kidney function
• A family history of any of the above – ADH1 is inherited in an autosomal dominant pattern, so a child of a parent with ADH1 has a 50% chance of inheriting it

📍 Upper Larimer (Parking Lot), 3034 Larimer St, Denver, CO 80205
📅 Nov 1st & 2nd
🕙 12pm–6pm

Can’t make it but interested in having the van come to you? Fill out our interest form: https://bit.ly/3Uyfa4J

10/26/2026

Liz has been her husband Art's care partner since he was diagnosed with hereditary ATTR-CM in 2023. She describes the role less as caregiving and more as partnership by being another set of ears at appointments, asking the questions, and noticing the changes Art doesn't always mention.

The part people don't see, she says, is the mental work: the constant, quiet attention.

Because hereditary ATTR can run in families, Liz has also taken on sharing what she's learned with their children and grandchildren, so they know their family health history and what to watch for.

Her advice to other care partners: don't be afraid to speak up when something doesn't seem right. And take time for yourself, even a few minutes a day.

This , we're recognizing care partners like Liz.

10/24/2026

Curelgmd2i Foundation hosted their first regional LGMD2I/R9 Patient & Community Event in Salt Lake City.

Organizing a meeting like this takes a lot of effort behind the scenes. By bringing the event to Utah, CureLGMD2i met families where they are, making it possible for more people to learn, connect with one another, and be heard.

Thank you to the CureLGMD2i team for their dedication to this community, and to everyone who took the time to attend.

We are proud to support this work.

10/21/2026

"A major problem for rare disease research is funding." – Guangping Gao, M.D., UMass Chan Medical School

Noa is one of more than 30 million Americans living with a rare disease.

Fewer than 5% of rare diseases have an FDA-approved treatment. For most families, a diagnosis still arrives with no answer attached — and they wait.

Noa's Story is about what changed, and about the parents, researchers, and advocates who refused to accept that answer.

Our thanks to the Greenwood family for sharing Noa with us, and to the UMass Chan Medical School for the years of work behind this moment.

Watch the full video on our Insights page: https://bit.ly/4z9U5fL

10/16/2026

For people living with chronic and their caregivers, learning about a begins with clear, accessible information. Take a closer look at what researchers hope to learn through the RECLAIM-HP Study and how the study medicine is given.

10/14/2026

“The first thing that pops up is that life expectancy is about ten. That was when we realized how bad it really was.” – Lori Greenwood, Noa's mother

Noa is one of more than 30 million Americans living with a rare disease.

Fewer than 5% of rare diseases have an FDA-approved treatment. For most families, a diagnosis still arrives with no answer attached — and they wait.

Noa's Story is about what changed, and about the parents, researchers, and advocates who refused to accept that answer.

Our thanks to the Greenwood family for sharing Noa with us, and to the UMass Chan Medical School for the years of work behind this moment.

Watch the full video on our Insights page: https://bit.ly/4z9U5fL

10/13/2026